Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo

This publication has 19 references indexed in Scilit:

• Nanoparticulate Alternatives for Drug Delivery
  ACS Nano, 2010
• Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer
  Journal of Controlled Release, 2010
• Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies
  Expert Opinion on Drug Delivery, 2009
• Intralymphatic Chemotherapy Using a Hyaluronan–Cisplatin Conjugate
  Journal of Surgical Research, 2008
• Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer
  JNCI: Journal of the National Cancer Institute, 2006
• A New Model for Lymphatic Metastasis: Development of a Variant of the MDA-MB-468 Human Breast Cancer Cell Line that Aggressively Metastasizes to Lymph Nodes
  Clinical & Experimental Metastasis, 2005
• Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model
  Endocrine-Related Cancer, 2005
• Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage i. results from a randomised trial
  European Journal of Cancer, 1997
• Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
  New England Journal of Medicine, 1995
• Prognosis following local recurrence in the conservatively treated breast cancer patient
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1991